Recursion Pharmaceuticals (RXRX) EBITDA Margin (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly EBITDA Margin came in at 1985.55% in Q1 2026, down 68770.0% YoY from N/an in Q1 2025, and down 551.34% on a QoQ basis from 304.84% in Q4 2025.
Recursion Pharmaceuticals (RXRX) EBITDA Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of EBITDA Margin data on file, last reported at 1985.55% in Q1 2026.
- Quarterly EBITDA Margin fell 68770.0% year-over-year to 1985.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 881.32% (up 7876.0% YoY) and the FY2025 annual result came in at 867.87%, down 5377.0% from the prior year.
- EBITDA Margin slipped to 1985.55% in Q1 2026, from 304.84% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 304.84% in Q4 2025 to a low of 4042.41% in Q4 2024.
- A 5-year average of 1156.03% and a median of 862.54% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin sank 313405 bps — and 2025, when it soared 373757 bps.
- Tracing RXRX's EBITDA Margin over 5 years: stood at 445.91% in 2022, then tumbled by 104 bps to 908.36% in 2023, then slumped by 345 bps to 4042.41% in 2024, then jumped by 92 bps to 304.84% in 2025, then slumped by 551 bps to 1985.55% in 2026.
- The last three EBITDA Margin figures came in at 1985.55% (Q1 2026), 304.84% (Q4 2025), and 3327.57% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -1,759.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,759.69% |
| Mar 31, 2026 | -1,985.55% |
| Dec 31, 2025 | -304.84% |
| Sep 30, 2025 | -3,327.57% |
| Jun 30, 2025 | -916.75% |
| Mar 31, 2025 | -1,297.85% |
| Dec 31, 2024 | -4,042.41% |
| Sep 30, 2024 | -377.10% |
| Jun 30, 2024 | -697.39% |
| Mar 31, 2024 | -698.42% |
| Dec 31, 2023 | -908.36% |
| Sep 30, 2023 | -945.12% |
| Jun 30, 2023 | -741.72% |
| Mar 31, 2023 | -575.78% |
| Dec 31, 2022 | -445.91% |
| Sep 30, 2022 | -475.48% |
| Jun 30, 2022 | -862.54% |
| Mar 31, 2022 | -1,049.71% |
| Dec 31, 2021 | -2,564.55% |
| Sep 30, 2021 | -1,831.18% |